Biopharmaceuticals Market - Growth, Trends, and Forecast (2020 - 2025)

The Biopharmaceuticals Market is segmented by product type (monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzymes, cell and gene therapies, synthetic immunomodulators, and other product type), therapeutic application, and geography

Market Snapshot

Study Period:


Base Year:


Fastest Growing Market:

Asia Pacific

Largest Market:

North America


7.32 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The global biopharmaceuticals market is found witnessing a CAGR of 7.32%. The market is largely driven by the growing geriatric population, increasing burden of chronic diseases, and rising inclination toward targeted therapy. Also, the huge demand of biopharmaceutical is facilitated by an accelerating focus in research and related investment.

The ability of biopharmaceutical products to address previously untreatable conditions has introduced innovative drugs in the market. About 70% of the potential medicines in development represent novel approaches to addressing diseases in areas, such as neurology, cancer, diabetes, and immunology. Biopharmaceuticals have thus seen to reduce the number of deaths due to cancer and HIV/AIDS in the past decade, which has led to an increase in the adoption of biopharmaceuticals in the global market.

In addition, the market demand for biopharmaceuticals is increasing with the rising desire to circumvent both the side-effects associated with some small-molecule therapeutics and invasive surgical treatments. However, high cost, along with the difficulty of the development of a biopharmaceutical drug, is one growth limiting factor.

Scope of the Report

As per the scope of the report, biopharmaceutical refers to any biologically synthesized molecule that is used to treat or manage disorders. Biopharmaceutical products include (but are not limited to) monoclonal antibodies, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, vaccines, recombinant enzyme, synthetic immunomodulators, cell and gene therapies, and other products.

By Product Type
Monoclonal Antibodies
Anti Cancer Monoclonal Antibodies
Anti-inflammatory Monoclonal Antibodies
Other Monoclonal Antibodies
Recombinant Growth Factors
Granulocyte Colony Stimulating Factor
Purified Proteins
Leukemia Inhibitory Factor (LIF)
P53 Protein
P38 Protein
Other Purified Proteins
Recombinant Proteins
Serum Albumin
Amyloid Protein
Recombinant Hormones
Recombinant Human Growth Hormones
Recombinant Insulin
Other Recombinant Hormones
Recombinant Vaccines
Cancer Vaccines
Malaria Vaccines
Ebola Vaccine
Hepatitis B Vaccine
Tetanus Vaccine
Diptheria Vaccine
Cholera Vaccine
Other Recombinant Vaccines
Conventional Vaccines
Polio Vaccine
Pox Vaccine
Other Conventional Vaccines
Recombinant Enzymes
Cell and Gene Therapies
Allogeneic Products
Autologous Products
Acellular Products
Synthetic Immunomodulators
Cytokines, Interferones, Interleukins
Other Product Types
Blood Factors
Other Product Types
By Therapeutic Application
Inflammatory and Infectious Diseases
Autoimmune Disorders
Metabolic Disorders
Hormonal Disorders
Cardiovascular Diseases
Neurological Diseases
Other Diseases
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle-East and Africa
South Africa
Rest of Middle-East & Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Monoclonal Antibodies is Expected to Hold a High Market Share During the Forecasted Period

Among the given segments, monoclonal antibodies are believed to have the largest market size. This can be attributed to the growing research done with the help of monoclonal antibodies. On the other hand, the recombinant enzymes segment is expected to show rapid growth during the forecast period. 

Monoclonal antibodies (mAbs) find their application in the areas of cancer treatment. Their use is becoming prevalent in developed countries, such as the United States and the United Kingdom. The mAb drugs in oncology are gaining momentum and growing at a decent pace. The segment is dominating the market currently, and the trend is expected to be followed in the future. 

The recombinant enzymes, such as Enterokinase, are gaining attraction because of their efficacy in the digestion of the dietary proteins. This application has improved the market scope for this particular enzyme in the recent years.

To understand key trends, Download Sample Report

North America Dominates the Market and Expected to do the Same in the Forecast Period

North America currently dominates the market for biopharmaceuticals, and is expected to continue its stronghold for a few more years. The United States has shown an incredible growth over the past several years. The country has been recognized as the innovation capital of the world for life sciences, and it is involved in global capital investments in the early stages of biopharmaceutical companies.

The United States holds the majority of the market in the North American region; this is due to the increasing prevalence of chronic diseases. In addition, there is a rise in per capita health expenditure in the country that is expected to increase over the forecast period, owing to the decrease in the unemployment rate.

To understand geography trends, Download Sample Report.

Competitive Landscape

The biopharmaceuticals market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products with less prices. Companies, like Amgen Inc., Eli Lily & Company, Johnson & Johnson, and Pfizer Inc. hold a significant share in the biopharmaceuticals market.

You can also purchase parts of this report. Do you want to check out a section wise price list?

Table Of Contents


    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Acceptance for Biopharmaceuticals

      2. 4.2.2 Ability of Biopharmaceuticals to Treat Previously Untreatable Diseases

      3. 4.2.3 Huge Market Demand

    3. 4.3 Market Restraints

      1. 4.3.1 High-end Manufacturing Requirements

      2. 4.3.2 Complicated and Cumbersome Regulatory Requirements


    1. 5.1 By Product Type

      1. 5.1.1 Monoclonal Antibodies

        1. Anti Cancer Monoclonal Antibodies

        2. Anti-inflammatory Monoclonal Antibodies

        3. Other Monoclonal Antibodies

      2. 5.1.2 Recombinant Growth Factors

        1. Erythropoietin

        2. Granulocyte Colony Stimulating Factor

      3. 5.1.3 Purified Proteins

        1. Leukemia Inhibitory Factor (LIF)

        2. P53 Protein

        3. P38 Protein

        4. Other Purified Proteins

      4. 5.1.4 Recombinant Proteins

        1. Serum Albumin

        2. Amyloid Protein

        3. Defensin

        4. Transferrin

      5. 5.1.5 Recombinant Hormones

        1. Recombinant Human Growth Hormones

        2. Recombinant Insulin

        3. Other Recombinant Hormones

      6. 5.1.6 Vaccines

        1. Recombinant Vaccines

          1. Cancer Vaccines

          2. Malaria Vaccines

          3. Ebola Vaccine

          4. Hepatitis B Vaccine

          5. Tetanus Vaccine

          6. Diptheria Vaccine

          7. Cholera Vaccine

          8. Other Recombinant Vaccines

        2. Conventional Vaccines

          1. Polio Vaccine

          2. Pox Vaccine

          3. Other Conventional Vaccines

      7. 5.1.7 Recombinant Enzymes

        1. Enterokinase

        2. Cyclase

        3. Caspase

        4. Cathepsin

      8. 5.1.8 Cell and Gene Therapies

        1. Allogeneic Products

        2. Autologous Products

        3. Acellular Products

      9. 5.1.9 Synthetic Immunomodulators

        1. Cytokines, Interferones, Interleukins

      10. 5.1.10 Other Product Types

        1. Blood Factors

        2. Other Product Types

    2. 5.2 By Therapeutic Application

      1. 5.2.1 Oncology

      2. 5.2.2 Inflammatory and Infectious Diseases

      3. 5.2.3 Autoimmune Disorders

      4. 5.2.4 Metabolic Disorders

      5. 5.2.5 Hormonal Disorders

      6. 5.2.6 Cardiovascular Diseases

      7. 5.2.7 Neurological Diseases

      8. 5.2.8 Other Diseases

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. United Kingdom

        2. Germany

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. India

        2. China

        3. Japan

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle-East & Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbvie Inc.

      2. 6.1.2 Amgen Inc.

      3. 6.1.3 Bristol-Myers Squibb Company

      4. 6.1.4 Eli Lily & Co.

      5. 6.1.5 Johnson & Johnson

      6. 6.1.6 Novartis AG

      7. 6.1.7 Novo Nordisk Inc.

      8. 6.1.8 Pfizer Inc.

      9. 6.1.9 GlaxoSmithKline PLC

      10. 6.1.10 F. Hoffmann-La Roche AG

  7. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Related Reports